9,446 Shares in Revolution Medicines, Inc. $RVMD Acquired by State of Wyoming

State of Wyoming purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 9,446 shares of the company’s stock, valued at approximately $1,769,000.

Several other institutional investors also recently modified their holdings of the stock. Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines during the 2nd quarter valued at $32,000. Global Retirement Partners LLC boosted its stake in shares of Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares in the last quarter. Torren Management LLC acquired a new position in shares of Revolution Medicines in the 4th quarter worth $33,000. Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the 4th quarter worth $38,000. Finally, Allworth Financial LP raised its position in shares of Revolution Medicines by 57.2% during the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after purchasing an additional 210 shares during the period. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Trading Up 0.8%

NASDAQ:RVMD opened at $203.71 on Friday. The stock has a market cap of $43.66 billion, a PE ratio of -23.10 and a beta of 1.39. Revolution Medicines, Inc. has a fifty-two week low of $35.42 and a fifty-two week high of $208.76. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The stock’s 50-day moving average is $181.62 and its two-hundred day moving average is $140.49.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the firm earned ($1.31) EPS. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RVMD. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Revolution Medicines in a report on Thursday, August 6th. Royal Bank Of Canada lifted their price target on Revolution Medicines from $182.00 to $203.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Guggenheim boosted their price objective on Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush upped their price objective on shares of Revolution Medicines from $192.10 to $201.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, Wolfe Research reiterated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $161.79.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 10,020 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $1,564,322.40. Following the transaction, the insider directly owned 267,330 shares of the company’s stock, valued at $41,735,559.60. This represents a 3.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the sale, the director directly owned 21,656 shares of the company’s stock, valued at $4,071,111.44. This trade represents a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 132,497 shares of company stock valued at $21,470,486. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.